Showing results (11-20 of 82) with videos related to
Sort By:
Pageof 9
Oncology Research and Treatment|October 5, 2018
Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal AdenocarcinomaAnna Schmitt, Georg Feldmann, Thomas Zander, et al.Innere Medizin (Heidelberg, Germany)|October 22, 2025
[What is established in the treatment of diffuse large B-cell lymphoma?]Stefan K Alig, H Christian Reinhardt, Bastian von TresckowEjhaem|March 13, 2026
Successful Treatment of Aplastic Anemia With Eltrombopag During Pregnancy: A Short ReportSandra M Frey, Ferras Alashkar, H Christian Reinhardt, et al.Cell Cycle (Georgetown, Tex.)|December 22, 2010
Is post-transcriptional stabilization, splicing and translation of selective mRNAs a key to the DNA damage response?H Christian Reinhardt, Ian G Cannell, Sandra Morandell, et al.Cell Cycle (Georgetown, Tex.)|September 17, 2009
Exploiting synthetic lethal interactions for targeted cancer therapyH Christian Reinhardt, Hai Jiang, Michael T Hemann, et al.Cancer Cell|February 13, 2007
p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damageH Christian Reinhardt, Aaron S Aslanian, Jacqueline A Lees, et al.Current Opinion in Hematology|April 28, 2018
DNA damage pathways and B-cell lymphomagenesisGero Knittel, Tim Rehkämper, Pascal Nieper, et al.Radiology Case Reports|August 31, 2021
Thymic hyperplasia after mRNA based Covid-19 vaccinationJulia von Tresckow, Bastian von Tresckow, H Christian Reinhardt, et al.European Journal of Haematology|December 22, 2025
Sutimlimab in Patients With Cold Agglutinin Disease (CAD): Results From a Managed Access ProgramSandra Maria Frey, Pauline Halberstadt, Ferras Alashkar, et al.Cancer Immunology, Immunotherapy : CII|September 12, 2018
Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilitiesAlexander N R Weber, Yamel Cardona Gloria, Özcan Çınar, et al.Pageof 9